Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial

Abstract

Background There is an urgent need for an effective tuberculosis (TB) vaccine. Heterologous prime–boost regimens induce potent cellular immunity. MVA85A is a candidate TB vaccine. This phase I clinical trial was designed to evaluate whether alternating aerosol and intradermal vaccination routes would boost cellular immunity to the Mycobacterium tuberculosis antigen 85A (Ag85A). Methods and findings Between December 2013 and January 2016, 36 bacille Calmette-Guérin–vaccinated, healthy UK adults were randomised equally between 3 groups to receive 2 MVA85A vaccinations 1 month apart using either heterologous (Group 1, aerosol–intradermal; Group 2, intradermal–aerosol) or homologous (Group 3, intradermal–intradermal) immunisation. Bronchoscopy and bronchoalveolar lavage (BAL) were performed 7 days post-vaccination. Adverse events (AEs) and peripheral blood were collected for 6 months post-vaccination. The laboratory and bronchoscopy teams were blinded to treatment allocation. One participant was withdrawn and was replaced. Participants were aged 21–42 years, and 28/37 were female. In a per protocol analysis, aerosol delivery of MVA85A as a priming immunisation was well tolerated and highly immunogenic. Most AEs were mild local injection site reactions following intradermal vaccination. Transient systemic AEs occurred following vaccination by both routes and were most frequently mild. All respiratory AEs following primary aerosol MVA85A (Group 1) were mild. Boosting an intradermal MVA85A prime with an aerosolised MVA85A boost 1 month later (Group 2) resulted in transient moderate/severe respiratory and systemic AEs. There were no serious adverse events and no bronchoscopy-related complications. Only the intradermal–aerosol vaccination regimen (Group 2) resulted in modest, significant boosting of the cell-mediated immune response to Ag85A ( p = 0.027; 95% CI: 28 to 630 spot forming cells per 1 × 10 6 peripheral blood mononuclear cells). All 3 regimens induced systemic cellular immune responses to the modified vaccinia virus Ankara (MVA) vector. Serum antibodies to Ag85A and MVA were only induced after intradermal vaccination. Aerosolised MVA85A induced significantly higher levels of Ag85A lung mucosal CD4+ and CD8+ T cell cytokines compared to intradermal vaccination. Boosting with aerosol-inhaled MVA85A enhanced the intradermal primed responses in Group 2. The magnitude of BAL MVA-specific CD4+ T cell responses was lower than the Ag85A-specific responses. A limitation of the study is that while the intradermal–aerosol regimen induced the most potent cellular Ag85A immune responses, we did not boost the last 3 participants in this group because of the AE profile. Timing of bronchoscopies aimed to capture peak mucosal response; however, peak responses may have occurred outside of this time frame. Conclusions To our knowledge, this is the first human randomised clin...

Combating COVID-19: MVA Vector Vaccines Applied to the Respiratory Tract as Promising Approach Toward Protective Immunity in the Lung

“…Furthermore, it has been shown that intranasal application of MVA expressing a secreted form of the bovine herpesvirus 1 (BoHV-1) glycoprotein D protects against BoHV-1 infection in a rabbit model (19). Application of MVA vector vaccines via the respiratory route has been shown to be safe in general (16) but respiratory adverse effects have been reported after intramuscular priming and inhalative boosting with MVA expressing the 85A antigen of Mycobacterium tuberculosis (20).…”

Effect of the Route of Administration of the Vaccinia Virus Strain LIVP to Mice on Its Virulence and Immunogenicity

“…It was found that the VACV strains can differ significantly in terms of their pathogenicity and reactogenicity. Furthermore, the route of inoculation with the virus can also significantly affect its pathogenic and immunogenic properties [21][22][23][24][25][26].…”

Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology

“…First phase IIb efficacy trials with this vaccine in neonates and in adults failed to provide protection (102,103). More recently, the vaccine has been tested for safety and immunogenicity after aerosol application (104,105). Other viral vectored vaccines include replication deficient adenovirus vectors expressing antigen Ag85A and a replication deficient H1N1 influenza vector expressing antigen Ag85A and ESAT-6.…”